Skip to Main Content
Table 2.

Cytotoxicity profiles of PR-171 and bortezomib

Cell typeCell lineOriginCell viability IC50 (nmol/L) 1 h treatment/72 h washout
Cell viability IC50 (nmol/L) 72 h treatment
PR-171BortezomibPR-171Bortezomib
Hematologic tumor RPMI 8226 Multiple myeloma 71 ± 22 303 ± 52 10 ± 3.3 4.5 ± 2.5 
 HS-Sultan B-cell lymphoma (Burkitt's) 135 ± 30 454 ± 60 5.2 ± 2.3 5.4 ± 2.0 
 Molt4 Acute lymphoblastic leukemia 31 ± 17 126 ± 52 3.1 ± 1.6 6.2 ± 2.7 
 RL B cell lymphoma (NHL) 164 ± 92 814 ± 476 2.4 ± 0.4 3.4 ± 2.0 
Solid tumor HT-29 Colorectal adenocarcinoma 350 ± 84 2,190 ± 390 6.2 ± 3.9 5.0 ± 2.6 
 MiaPaCa-2 Pancreatic carcinoma 1,110 ± 240 >6,500 8.9 ± 6.5 8.3 ± 2.3 
 A549 Lung carcinoma 1,200 ± 900 4,600 ± 1,900 20 ± 8 13 ± 8 
Nontransformed NHDF Normal skin 389 ± 128 2,460 ± 1,120 14 ± 4.5 6.3 ± 4.1 
 HUVEC Normal umbilical vein 455 ± 45 3,510 ± 390 7.2 ± 1.3 3.5 ± 0.5 
Cell typeCell lineOriginCell viability IC50 (nmol/L) 1 h treatment/72 h washout
Cell viability IC50 (nmol/L) 72 h treatment
PR-171BortezomibPR-171Bortezomib
Hematologic tumor RPMI 8226 Multiple myeloma 71 ± 22 303 ± 52 10 ± 3.3 4.5 ± 2.5 
 HS-Sultan B-cell lymphoma (Burkitt's) 135 ± 30 454 ± 60 5.2 ± 2.3 5.4 ± 2.0 
 Molt4 Acute lymphoblastic leukemia 31 ± 17 126 ± 52 3.1 ± 1.6 6.2 ± 2.7 
 RL B cell lymphoma (NHL) 164 ± 92 814 ± 476 2.4 ± 0.4 3.4 ± 2.0 
Solid tumor HT-29 Colorectal adenocarcinoma 350 ± 84 2,190 ± 390 6.2 ± 3.9 5.0 ± 2.6 
 MiaPaCa-2 Pancreatic carcinoma 1,110 ± 240 >6,500 8.9 ± 6.5 8.3 ± 2.3 
 A549 Lung carcinoma 1,200 ± 900 4,600 ± 1,900 20 ± 8 13 ± 8 
Nontransformed NHDF Normal skin 389 ± 128 2,460 ± 1,120 14 ± 4.5 6.3 ± 4.1 
 HUVEC Normal umbilical vein 455 ± 45 3,510 ± 390 7.2 ± 1.3 3.5 ± 0.5 

NOTE: Cell viability was measured with CellTiter-Glo reagent either after continuous compound exposure for 72 h or with 1 h compound exposure followed by a 72 h washout period. Values reported are the mean ± SD from ≥3 determinations.

Close Modal

or Create an Account

Close Modal
Close Modal